Key Highlights

  • GSK plc (LSE:GSK) closed about 4.8% lower on 28 October 2026 after third-quarter results, ranking among the FTSE 100's biggest fallers.
  • Q3 revenue rose 5% at constant exchange rates to £8,887 million, slightly ahead of market forecasts.
  • Vaccines sales fell 2% to £2,583 million, while Specialty Medicines grew 15% to £3,877 million.
  • Full-year 2026 guidance was left unchanged, with revenue growth expected in the upper half of the 3% to 5% range.

Why GSK Is in Focus Today

GSK plc (LSE:GSK) was one of the heaviest drags on the FTSE 100 on 28 October 2026 after its third-quarter update. The shares fell sharply in early trading and closed around 4.8% lower, even though headline revenue edged past market expectations and management kept its annual outlook intact.

The reaction centred on the vaccines business. Sales in the division slipped 2% to £2,583 million, falling short of what the market had pencilled in. For a group where vaccines remain a major profit pool, that shortfall raised concern that trading could be tougher in the coming quarters.

Inside the Third-Quarter Numbers

Total revenue rose 5% at constant exchange rates to £8,887 million, about 1% above consensus. Specialty Medicines continued to lead growth, rising 15% to £3,877 million, supported by areas such as HIV, oncology and respiratory and immunology treatments.

Total operating profit fell 16% to £2,127 million. Investors often focus on core measures that strip out items such as litigation and restructuring, but the headline decline added to the cautious tone around the release.

GSK (LSE:GSK) left 2026 guidance unchanged, still expecting revenue growth of 3% to 5% and pointing to the upper half of that range. Specialty Medicines is still expected to deliver a low double-digit increase in sales for the year.

Why Vaccines Matter So Much

Vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus have been central to GSK's growth story in recent years. However, the category has faced pressure from tougher comparisons, changing public health priorities in the United States and slower uptake in some adult vaccination programmes.

GSK had already guided that vaccine sales in 2026 could range from a low single-digit decline to stable. A 2% fall in the quarter is broadly consistent with that, but markets had hoped for a steadier performance. The miss reinforced worries that the division may remain a drag while newer medicines build scale.

Leadership and Pipeline Context

Chief Executive Luke Miels is now leading the group, and investors appear to want firmer evidence that the pipeline can offset upcoming patent expiries later this decade. GSK has highlighted new launches and late-stage readouts as key drivers, but the market reaction suggests patience is limited until those products contribute meaningfully to revenue.

Pharmaceutical stocks also face policy uncertainty, including US drug pricing measures and tariffs. GSK has previously said its guidance includes the impact of tariffs enacted so far, but any new policy changes would remain a risk for the sector.

What Investors Are Watching Next

The next set of signals will come from pipeline updates, regulatory decisions and data readouts expected into year-end. Investors will also look for evidence that vaccine trends stabilise in the fourth quarter, particularly in the United States.

Sector news is another factor. AstraZeneca reports its results on 30 October, which could influence sentiment toward UK-listed pharmaceutical shares. Shareholders will also track GSK's quarterly dividend and any update on capital allocation when full-year results are published early next year.

How the Market Read the Release

The share price reaction was striking given that revenue came in about 1% ahead of forecasts and guidance was reaffirmed. At one stage during the morning, GSK (LSE:GSK) was down around 6% to 7% before recovering slightly into the close. The stock was the second-largest faller in the FTSE 100 on the day, behind only Barratt Redrow.

Part of the reaction may reflect positioning. Pharmaceutical shares are widely held by income-focused and defensive investors, and any sign that a core franchise is losing momentum can trigger rapid portfolio adjustments. With Unilever also falling on the same morning despite raising its volume outlook, defensive large caps were broadly out of favour as banks and utilities attracted buyers following the Budget.

Analysts will now revisit forecasts for the vaccines division into 2027. Even small changes to assumptions for Shingrix and Arexvy can have a sizeable impact on earnings expectations, given the high margins these products typically carry.

Outlook

GSK (LSE:GSK) delivered growth where it counts most for the long term, namely Specialty Medicines, while keeping its guidance unchanged. Yet the 28 October pullback shows the market is focused on near-term weak spots. Whether the shares recover will depend on how quickly vaccines stabilise and how convincingly the pipeline fills the gap left by maturing products.